We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials.
- Authors
Xiong, Xiao-feng; Zhu, Min; Wu, Hong-xia; Fan, Li-li; Cheng, De-yun
- Abstract
<bold>Background: </bold>Several recent clinical trials have assessed the effects of dupilumab in uncontrolled asthma, but reached no definite conclusion. We therefore conducted this meta-analysis to evaluate the overall efficacy and safety of dupilumab for the treatment of uncontrolled asthma.<bold>Methods: </bold>All randomized controlled trials were included. Standard mean differences (SMD) or relative risks (RR) were calculated using Fixed-or random-effects models.<bold>Results: </bold>Five studies involving 3369 patients were identified. Pooled analysis showed significant improvements in the first-second forced expiratory volume (FEV1) (SMD = 4.29, 95% CI: 2.78-5.81) and Asthma Quality of Life Questionnaire scores (SMD = 4.39, 95% CI: 1.44-7.34). Dupilumab treatments were also associated with significantly decreased 5-item Asthma Control Questionnaire scores (SMD = - 4.95, 95% CI: - 7.30 to - 2.60), AM and PM asthma symptom scores (SMD = - 5.09, 95% CI: - 6.40 to - 3.77; SMD = - 4.92, 95% CI: - 5.98 to - 3.86, respectively), and severe exacerbation risk (RR = 0.73; 95% CI: 0.67-0.79) compared with placebo, with similar incidence of adverse events (RR = 1.0; 95% CI: 0.96-1.04).<bold>Conclusion: </bold>Dupilumab treatment is relatively well-tolerated and could significantly improve FEV1, symptoms, asthma control, and quality of life, and reduced severe exacerbation risk in patients with uncontrolled asthma.
- Subjects
ASTHMA treatment; META-analysis; DRUG efficacy; MEDICATION safety; THERAPEUTIC use of monoclonal antibodies; DUPILUMAB
- Publication
Respiratory Research, 2019, Vol 20, Issue 1, pN.PAG
- ISSN
1465-9921
- Publication type
journal article
- DOI
10.1186/s12931-019-1065-3